Prolight Diagnostics publishes year-end report 2024
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, Q4 2024 Group• Net sales amounted to 0 (0).• Other operating income amounted to 15,317 (11,580) TSEK.• Profit after tax amounted to 2,011 (-110,094) TSEK.• Earnings per share before and after dilution: 0.00 (-0.32) SEK.• […]
Prolight receives second Notice of Intention to Grant from European Patent Office for Psyros™ technology
Prolight Diagnostics announces today that the company have received a Notice of Intention to Grant from the European Patent Office (EPO) for their second patent application related to the Psyros™ technology. This application (EP 4264266) is an extension to the core application (EP 3987287). This application is an extension of the core patent to include […]
Prolight receives Notice of Intention to Grant for core Psyros™ patent
Prolight Diagnostics announces today that they have received a Notice of Intention to Grant from the European Patent Office (EPO) for patent protection of their single molecule counting POC technology. This is the first application that will be granted in any territory for the Psyros™ technology. This application (EP 3987287) protects the fundamental measurement system […]
Prolight Diagnostics publishes investor letter for December 2024
In 2024, Prolight has achieved many business-critical milestones, positioning the company optimally for 2025 and on track for its planned commercial launch in 2026. link to the investor letter: https://prolightdx.com/PRLD-Investerarbrev-dec-2024-EN.pdf For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These […]
Prolight strengthens IP portfolio by additional patent application
Prolight is pleased to announce the filing of a sixth patent application relating to the Psyros™ high-sensitivity IVD platform. The Psyros™ system enables cost-effective high-sensitivity testing at the point-of-care through its single-molecule-counting technology. This new patent application enhances Prolight’s existing IP portfolio. The latest patent application builds upon the existing portfolio and allows any type […]
EMERGERS VALUE PROLIGHT DIAGNOSTICS AT 730 MSEK (0,9- 1,0 SEK PER SHARE)
In the analysis from Emergers you can e.g. read that: “The arrival of the first of thirty full commercial prototypes marks a pivotal moment” ” Prolight achieved several key technical milestones in Q3’24 as the September business review demonstrated cost-efficient, scalable cartridge production, eliminating the need for expensive liquid reagents and enabling multiplex biomarker […]
Prolight achieves significant milestone with arrival of first Psyros™ commercial prototype instruments
Prolight is proud to announce the arrival of the first of thirty full commercial prototype instruments of its groundbreaking Psyros™ Point of Care (POC) system from its development partner G&H I ITL. This lays the foundation for the pre-validation study and subsequent clinical performance study in 2025, in-line with the timeline towards commercial launch in […]
The nomination committee appointed for the Annual General Meeting 2025.
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting. The nomination committee’s task is to produce proposals for the AGM regarding […]
Prolight Diagnostics publishes quarterly report Q3, 2024
Financial overviewThird quarter, 1 July – 30 September, Q3 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 3,730 (28) thousand. The profit after tax amounted to SEK -8,795 (-9,755) thousand. Earnings per share before and after dilution: -0.01 […]
Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
